Effects of liraglutide or lifestyle counselling on subcutaneous adipose tissue and visceral adipose tissue distribution, circulating adipokine concentration, insulin sensitivity and beta-cell performance (Effetti di liraglutide o interventi sullo stile di vita sulla distribuzione del tessuto adiposo viscerale e sottocutaneo, la concentrazione di adipochine circolanti, la sensibilità insulinica e la performance beta-cellulare)

Trial Profile

Effects of liraglutide or lifestyle counselling on subcutaneous adipose tissue and visceral adipose tissue distribution, circulating adipokine concentration, insulin sensitivity and beta-cell performance (Effetti di liraglutide o interventi sullo stile di vita sulla distribuzione del tessuto adiposo viscerale e sottocutaneo, la concentrazione di adipochine circolanti, la sensibilità insulinica e la performance beta-cellulare)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top